文献速递肝胆胰外科围术期管理与 ERAS

胰腺切除术联合动脉切除的适应证与围术期结局

Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection.
PubMed 文献 · J Am Coll Surg · 2018-05-09

单中心1990至2017年111例择期胰腺切除联合动脉切除(AR)的回顾性分析显示,90天主要并发症(≥III级)54%、死亡率13%,主要死因为胰切除后出血(PPH)、胰瘘(POPF)或缺血;2010年后死亡率显著下降(9% vs 29%,p=0.02),PPH增加死亡风险(OR 6.1,p<0.001);中位生存28.5个月,导管腺癌新辅助化疗后生存改善(p=0.038)。

要点

  • 胰腺切除联合动脉切除的90天主要并发症54%、死亡率13%,风险高于标准切除。
  • 2010年后死亡率显著下降(9% vs 29%,p=0.02),但并发症仍高。
  • PPH增加死亡风险(OR 6.1,p<0.001),并与再手术、ICU入住等相关。

核心结论

  • 无论适应证或动脉切除类型,胰腺切除联合动脉切除的风险均高于标准切除。
  • 现代(2010年后)死亡率下降,但出血、瘘或缺血相关并发症导致的发病率仍高。
  • 鉴于现代化疗后部分病例的潜在肿瘤学获益,若更频繁考虑扩大切除,需采取缓解措施。

研究设计与样本

  • 单中心回顾性综述,纳入1990年7月至2017年7月择期胰腺切除联合动脉切除(AR)的111例患者。
  • 进行单因素和多因素分析,评估结局、死亡率和生存的预测因素。

主要发现

  • 111例中肝动脉切除54%、腹腔干切除44%、肠系膜上动脉切除14%、多支动脉切除14%,55%行血管重建。
  • 77%为计划性手术,78%在2010年后完成。
  • 90天主要并发症(≥III级)为54%,死亡率为13%,多数死于胰切除后出血(PPH)、术后胰瘘(POPF)或缺血。
  • 2010年后死亡率显著下降(9% vs 29%,p=0.02),多因素分析显示保护作用(OR 0.1,p=0.004);PPH增加死亡风险(OR 6.1,p<0.001)。
  • PPH与主要并发症(OR 5.1,p=0.005)、再手术(OR 23.0,p=0.004)、ICU入住(OR 5.5,p<0.001)和再入院(OR 2.6,p=0.004)相关;其他并发症预测因素包括带移植物的AR(OR 4.0,p=0.031)和POPF(OR 3.1,p=0.003)。

临床怎么用

  • 对于考虑胰腺切除联合动脉切除的病例,应充分评估高于标准切除的风险,并关注2010年后死亡率下降但并发症仍高的现实。
  • 围术期应重点预防和处理胰切除后出血、胰瘘和缺血相关并发症,以降低死亡和再手术风险。
  • 在 selected 病例中,现代化疗后动脉切除可能带来肿瘤学获益,但需采取缓解措施。

局限性

  • 单中心回顾性研究,样本量111例,可能存在选择偏倚。
  • 研究跨越1990至2017年,治疗和围术期管理随时间变化可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatectomy with arterial resection (AR) is performed infrequently. As indications evolve, we evaluated indications, outcomes, and predictors of mortality, morbidity, and survival after AR. STUDY DESIGN: We performed a single-institution review of elective pancreatectomies with AR (from July1990 to July 2017). Univariate and multivariate analyses were performed for predictors of outcomes and survival. RESULTS: A total of 111 patients underwent pancreatectomy with AR including any hepatic (54%), any celiac (44%), any superior mesenteric (14%), or multiple ARs (14%), with revascularization in 55%. The majority of cases were planned (77%) and performed post-2010 (78%). Overall 90-day major morbidity (≥grade III) and mortality were 54% and 13%, respectively, due to post-pancreatectomy hemorrhage (PPH), postoperative pancreatic fistula (POPF), or ischemia in the majority of cases. There was a significant decrease in mortality post-2010 (9% vs 29%, p = 0.02), and this was protective on multivariate analysis (odds ratio [OR] 0.1, p = 0.004); PPH increased mortality (OR 6.1, p < 0.001). Post-pancreatectomy hemorrhage was associated with major morbidity (OR 5.1, p = 0.005), reoperation (OR = 23.0, p = 0.004), ICU (OR 5.5, p < 0.001), and readmission (OR 2.6, p = 0.004). Other morbidity predictors were AR with graft (OR 4.0, p = 0.031) and POPF (OR 3.1, p = 0.003). Median survival was 28.5 months and improved for ductal adenocarcinoma after neoadjuvant chemotherapy (p = 0.038). There were no differences in survival based on AR type. CONCLUSIONS: Regardless of indication or type, pancreatectomy with AR is associated with risks greater than standard resections. Mortality has decreased in the modern era; however, morbidity remains high from hemorrhagic, fistula, or ischemia-related complications. Mitigation measures are needed if advanced resections are considered with increasing frequency given the potential oncologic benefit of AR in selected cases after modern chemotherapy.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Tee MC, Krajewski AC, Groeschl RT, et al. Indications and Perioperative Outcomes for Pancreatectomy with Arterial Resection. J Am Coll Surg. 2018. PMID: 29752997. doi:10.1016/j.jamcollsurg.2018.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。